… MEK/PI3K inhibition in pancreatic ductal adenocarcinoma (PDAC). MEK inhibitors were the
… screen of 50 clinically relevant drugs in >500 human cancer cell lines. In combination with …

… PI3K inhibitor, LY294002, or transfection of a dominant negative mutant of Akt, inhibited
IKK and NF-κB activity in pancreatic cancer … NF-κB in pancreatic cancer cell lines was Akt/PI3K- …

… particular Class I PI3K isoforms for pancreatic cancer treatment. Isoform-specificity of PI3K
inhibitors are currently designed to achieve the same goal as pan-PI3K inhibitors but without …

… -0941, RG7621), a pan-Pi3K inhibitor, had minimal antitumor efficiency and was not well …
treating pancreatic cancer patients. In this review, we focus on PI3K/AKT/mTOR inhibitors that …

… , as it improved the anticancer drug efficacy by inhibiting the PI3K … , the PI3K inhibitor
LY294002 has been shown to enhance PI3K-dependent AKT phosphorylation in pancreatic cancer …

… of ERK1/2, MEK, and the parallel PI3K–AKT pathways, partly through engagement of the …
to tolerate ERK inhibition. Supporting this notion, we showed that pan-HER and PI3K inhibitors …

… More recently, olaparib, a PARP inhibitor, has received FDA approval for pancreatic cancer
patients harboring germline BRCA1 or BRCA2 mutations, presenting the first biomarker-…

… for treating pancreatic cancer patients with … , a PI3K inhibitor on the EMT in pancreatic cancer
and to identify its possible mechanism of action. Herein, we found that HS-173 inhibited TGF…

… discovery of a subtype of pancreatic adenocarcinoma that might be … PI3K in the pancreas
and examine the response of PIK3CA mutant pancreatic cancer to dual PI3K/mTOR inhibition…

… cell proliferation to the same degree as PI3K pathway inhibitors, indicating that multiple
RTK pathways feed into PI3K activation in PDAC and that PI3K inhibition may provide an …